Share Prices & Company Research

Market News

28 Jul 2021 | 12:32

GSK and Vir Biotechnology to supply EU with Covid-19 treatment

(Sharecast News) - GlaxoSmithKline has inked a joint procurement deal with Brussels for its Covid-19 treatment Sotrovimab together with its partner Vir Biotechnology. Under the terms of the agreement, the companies will supply the European Union with up to 220,000 doses of its experimental treatment.

Sotrovimab is aimed at adults and adolescents, aged 12 years and over, not requiring oxygen supplementation but who are at risk of developing severe forms of the disease.

Commenting on the news, GSK senior vice president, George Katzourakis, said the present deal was "crucial" as the pandemic continues evolving with an "urgent" need for treatment options.

Results from the firms' third phase clinical trial, which were published in June, had shown a 79% decrease in hospitalisations and deaths by Day 29 in comparison to placebo.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.